SG&A Expenses: A Tale of Two Biotechs

Exelixis, Inc. vs. Novavax, Inc.

In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Exelixis saw a staggering 967% increase in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Novavax's expenses surged by 2,254%, peaking in 2022, likely due to its pivotal role in COVID-19 vaccine development.

Key Insights

• Exelixis, Inc.: From a modest start in 2014, Exelixis's SG&A expenses grew consistently, reaching their zenith in 2023.
• Novavax, Inc.: A significant jump in 2020 marked the beginning of a rapid rise, aligning with its vaccine endeavors.

These trends highlight the strategic financial maneuvers of these biotech giants, offering a window into their operational priorities.